<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
Trade with 70% Backtested Accuracy
Analyst Views on 01801
About the author
<Daily Summary> HSI Gains 435 Points; HSTI Rises 151 Points; XIAOMI, BABA, and TENCENT Each Increase by Over 3%; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) rose by 435 points (1.7%) to close at 25,757, with significant gains also seen in the HSTI and HSCEI, which increased by 151 points (3.2%) and 176 points (2.1%) respectively, and market turnover reached $292.77 billion.
Top Gainers: Notable heavyweights like Xiaomi, Alibaba, and Tencent saw increases of 3.8%, 3.5%, and 3.4% respectively, while JD Logistics surged by 22.98%, and JD gained 9.95%.
Short Selling Activity: High short selling ratios were observed in several stocks, with JD having a ratio of 43.477% and Meituan at 26.184%, indicating significant market speculation.
Other Notable Stocks: Companies like Geely Auto, Trip.com, and Mengniu Dairy also experienced substantial gains, with increases of 7.9%, 7.2%, and 6.9% respectively, reflecting a positive trend in various sectors.
<Midday Update> HSI Rises by 468 Points; HSTI Gains 177 Points; XIAOMI Surges Over 5%; BABA Increases Over 4%; TENCENT Climbs Over 3%
Market Performance: The Hang Seng Index (HSI) rose by 468 points (1.9%) to 25,789, while the Hang Seng Tech Index (HSTI) increased by 177 points (3.7%) to 4,973, and the Hang Seng China Enterprises Index (HSCEI) gained 187 points (2.2%) to 8,638.
Top Gainers: Notable stock performances included JD Logistics, which surged 21.3%, JD up 8.5%, and Trip.com rising 7.0%. Major companies like Xiaomi, Alibaba, and Tencent also saw significant increases in their stock prices.
Short Selling Activity: High short selling volumes were reported for several stocks, with Alibaba and JD having short selling ratios of 16.072% and 50.972%, respectively, indicating investor caution despite their price increases.
Other Notable Movements: Stocks like TransThera and Bayzed Health experienced substantial gains of 34.9% and 21.5%, respectively, while Chinahongqiao saw a decline of 3.3%, reflecting varied performance across different sectors.
<Midday Update> HSI Ends Midday at 25,462, Gaining 212 Points; HSTI Remains Unchanged at 4,829; SINO BIOPHARM Rises More Than 5%; KINETIC DEV Reaches New Peaks
Market Performance: The Hang Seng Index (HSI) rose by 212 points (0.8%) to 25,462, while the Hang Seng China Enterprises Index (HSCEI) gained 20 points (0.2%) to 8,504.
Active Heavyweights: Notable movements included Meituan down 1.7%, Xiaomi up 1.6%, HKEX up 1.4%, Alibaba down 1.2%, and Tencent up 0.5%.
Top Gainers: Significant gainers included Sino Biopharm (+5.9%), AIA (+4.0%), Wharf REIC (+3.6%), and HSBC Holdings (+3.1%).
Notable Declines: WestChinaCement saw a sharp decline of 23.8%, while IFBH experienced a substantial increase of 24.3%.
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
M Stanley Resumes Coverage of INNOVENT BIO with Overweight Rating; Key Catalysts for CN Biotech Sector Expected in Second Half of 2026
China's Biotech Sector Outlook: Morgan Stanley reports that China's biotech sector is stabilizing with a resilient innovation base and ongoing financing recovery, but faces challenges due to geopolitical uncertainties and limited investment themes in 1H26.
Market Fluctuations and Future Growth: The sector is expected to experience range-bound fluctuations in 1H26, with potential for clearer stock price direction in 2H26 as meaningful data releases and licensing transactions emerge.
Investment Strategy: A broader de-risking sector rotation is anticipated, putting pressure on high Beta biotech sectors, while capital reallocation and favorable valuations may support future growth.
Coverage on INNOVENT BIO: Morgan Stanley has reinitiated coverage on INNOVENT BIO with an Overweight rating and a target price of HKD130, along with adjustments to target prices for other stocks.
HSI Closes Down 384 Points on Futures Settlement Day; Declines in Tech, Auto, Consumer, and Pharma Sectors
Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.
CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.
Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.
Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.
<Daily Summary> HSI Gains 435 Points; HSTI Rises 151 Points; XIAOMI, BABA, and TENCENT Each Increase by Over 3%; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) rose by 435 points (1.7%) to close at 25,757, with significant gains also seen in the HSTI and HSCEI, which increased by 151 points (3.2%) and 176 points (2.1%) respectively, and market turnover reached $292.77 billion.
Top Gainers: Notable heavyweights like Xiaomi, Alibaba, and Tencent saw increases of 3.8%, 3.5%, and 3.4% respectively, while JD Logistics surged by 22.98%, and JD gained 9.95%.
Short Selling Activity: High short selling ratios were observed in several stocks, with JD having a ratio of 43.477% and Meituan at 26.184%, indicating significant market speculation.
Other Notable Stocks: Companies like Geely Auto, Trip.com, and Mengniu Dairy also experienced substantial gains, with increases of 7.9%, 7.2%, and 6.9% respectively, reflecting a positive trend in various sectors.
<Midday Update> HSI Rises by 468 Points; HSTI Gains 177 Points; XIAOMI Surges Over 5%; BABA Increases Over 4%; TENCENT Climbs Over 3%
Market Performance: The Hang Seng Index (HSI) rose by 468 points (1.9%) to 25,789, while the Hang Seng Tech Index (HSTI) increased by 177 points (3.7%) to 4,973, and the Hang Seng China Enterprises Index (HSCEI) gained 187 points (2.2%) to 8,638.
Top Gainers: Notable stock performances included JD Logistics, which surged 21.3%, JD up 8.5%, and Trip.com rising 7.0%. Major companies like Xiaomi, Alibaba, and Tencent also saw significant increases in their stock prices.
Short Selling Activity: High short selling volumes were reported for several stocks, with Alibaba and JD having short selling ratios of 16.072% and 50.972%, respectively, indicating investor caution despite their price increases.
Other Notable Movements: Stocks like TransThera and Bayzed Health experienced substantial gains of 34.9% and 21.5%, respectively, while Chinahongqiao saw a decline of 3.3%, reflecting varied performance across different sectors.
<Midday Update> HSI Ends Midday at 25,462, Gaining 212 Points; HSTI Remains Unchanged at 4,829; SINO BIOPHARM Rises More Than 5%; KINETIC DEV Reaches New Peaks
Market Performance: The Hang Seng Index (HSI) rose by 212 points (0.8%) to 25,462, while the Hang Seng China Enterprises Index (HSCEI) gained 20 points (0.2%) to 8,504.
Active Heavyweights: Notable movements included Meituan down 1.7%, Xiaomi up 1.6%, HKEX up 1.4%, Alibaba down 1.2%, and Tencent up 0.5%.
Top Gainers: Significant gainers included Sino Biopharm (+5.9%), AIA (+4.0%), Wharf REIC (+3.6%), and HSBC Holdings (+3.1%).
Notable Declines: WestChinaCement saw a sharp decline of 23.8%, while IFBH experienced a substantial increase of 24.3%.
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
M Stanley Resumes Coverage of INNOVENT BIO with Overweight Rating; Key Catalysts for CN Biotech Sector Expected in Second Half of 2026
China's Biotech Sector Outlook: Morgan Stanley reports that China's biotech sector is stabilizing with a resilient innovation base and ongoing financing recovery, but faces challenges due to geopolitical uncertainties and limited investment themes in 1H26.
Market Fluctuations and Future Growth: The sector is expected to experience range-bound fluctuations in 1H26, with potential for clearer stock price direction in 2H26 as meaningful data releases and licensing transactions emerge.
Investment Strategy: A broader de-risking sector rotation is anticipated, putting pressure on high Beta biotech sectors, while capital reallocation and favorable valuations may support future growth.
Coverage on INNOVENT BIO: Morgan Stanley has reinitiated coverage on INNOVENT BIO with an Overweight rating and a target price of HKD130, along with adjustments to target prices for other stocks.
HSI Closes Down 384 Points on Futures Settlement Day; Declines in Tech, Auto, Consumer, and Pharma Sectors
Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.
CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.
Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.
Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.
